PROTOCOL FOR THE SCOTTISH POSTMENOPAUSAL CHEMO-ENDOCRINE TRIAL
OBJECTIVES: I. Compare the potential benefits of adjuvant tamoxifen with or without
cyclophosphamide, methotrexate, and fluorouracil (CMF) in postmenopausal women with stage
I-IIIA, unilateral, invasive breast cancer.
OUTLINE: This is a randomized study, multicenter study. Patients are stratified according to
nodal status (positive vs negative or unknown) and hospital region. Patients undergo
surgical resection with or without local radiotherapy, as appropriate. Radiotherapy begins
within 8 weeks of surgery for patients randomized to arm I and within 4 weeks after
completion of chemotherapy for patients randomized to arm II. Patients are randomized to 1
of 2 treatment arms, preferably within 2 weeks after surgery. Arm I: Beginning within 4
weeks after surgery, patients receive oral tamoxifen daily. Treatment continues for 5 years.
Arm II: Beginning within 4 weeks after surgery, patients receive tamoxifen as in arm I and
cyclophosphamide IV, methotrexate IV, and fluorouracil IV on day 1 (CMF). Chemotherapy
continues every 3 weeks for 6 courses. Patients are followed every 6 months for 5 years and
then annually thereafter.
PROJECTED ACCRUAL: A total of 1,000 patients will be accrued for this study.
Allocation: Randomized, Primary Purpose: Treatment
W.D. George, MD, MS, FRCS
University of Glasgow
United States: Federal Government